Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infusional ECF versus conventional FEC as adjuvant chemotherapy for poor prognosis breast cancer
ISRCTN83324925Phase 3Completed
- Sponsor
- The Institute of Cancer Research
- Start
- Jun 1995
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of epirubicin, cyclophosphamide and fluorouracil in breast cancer (2 arms), sponsored by The Institute of Cancer Research. Started Jun 1995; status: completed.
02
Drugs
epirubicincyclophosphamidefluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN83324925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN83324925.